David Evans is ranked #1012 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

David Evans (Kepler Capital ) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are David Evans's stock ratings?

About 62% of David's ratings were profitable over a one-year hold, with an average return of +9.5% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/David Evans

KEPL

David Evans

Kepler Capital

Wall Street Analyst

★★★☆☆

#1012

on 13Foresight · ranked by our own returns

38%

Success Rate

-0.3%

Average Return

3 of 8 calls profitable · -11.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 38% of David Evans's ratings turned a profit when each position was held for 2 year — averaging -0.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 19 Hold 0 Sell

David's Stock Coverage 36 ratings · 2026-06-24

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
GB:0QIU Novo Nordisk	May 22, 2026	HOLD	Hold +39.3% avg upside 29 analysts	$290.00 0.47% Downside	·
CH:NOVN Novartis AG	May 08, 2026	BUY	Buy -12.7% avg upside 30 analysts	$135.00 12.21% Upside	·
DE:MRK Merck KGaA	May 01, 2026	BUY	Strong Buy +1.1% avg upside 32 analysts	$152.00 14.19% Upside	·
GB:AZN AstraZeneca	Apr 29, 2026	HOLD	Strong Buy +10.0% avg upside 26 analysts	$11300.00 14.90% Downside	·
GB:GSK GlaxoSmithKline	Apr 29, 2026	HOLD	Hold -3.7% avg upside 25 analysts	$1500.00 22.08% Downside	·
CH:ROP Roche Holding AG	Apr 23, 2026	BUY	Strong Buy +2.4% avg upside 23 analysts	$415.00 30.32% Upside	·
GB:0NZT UCB SA	Mar 11, 2026	HOLD	Buy -13.4% avg upside 19 analysts	$260.00 4.20% Upside	·
FR:SAN Sanofi	Jan 30, 2025	HOLD	Strong Buy +34.5% avg upside 30 analysts	$92.00 26.82% Upside	·
CH:ALC Alcon	Aug 21, 2024	SELL	Buy +33.9% avg upside 35 analysts	$62.00 17.40% Upside	·
FR:EAPI Euroapi SA	Mar 08, 2023	BUY	Buy +545.1% avg upside 5 analysts	$17.00 1288.91% Upside	·
GB:0G99 Oxurion NV	Jul 07, 2021	HOLD	Hold +962.2% avg upside 2 analysts	$2.90 962.18% Upside	·
FR:TNG Transgene	Jul 07, 2021	BUY	Strong Buy +462.2% avg upside 1 analyst	$4.20 462.22% Upside	·
FR:OSE OSE Immunotherapeutics SA	Jul 07, 2021	BUY	Strong Buy +235.4% avg upside 4 analysts	$16.80 391.52% Upside	·
CH:BSLN Basilea Pharmaceutica	Jul 07, 2021	BUY	Strong Buy +43.4% avg upside 6 analysts	$67.00 31.54% Upside	·
FR:ALQGC Quantum Genomics Societe Anonyme	Jul 07, 2021	BUY	Strong Buy +11966.6% avg upside 1 analyst	$8.70 11966.56% Upside	·
IPHA Innate Pharma	Jul 07, 2021	BUY	Strong Buy +253.7% avg upside 10 analysts	$5.71 215.72% Upside	-6.9%
NBTX Nanobiotix	Jul 07, 2021	BUY	Strong Buy -6.3% avg upside 5 analysts	$29.71 15.75% Downside	-64.9%
DE:FYB Formycon AG	Jul 07, 2021	HOLD	Strong Buy +152.9% avg upside 5 analysts	$65.00 231.62% Upside	·
FR:ALGAE Fermentalg SA	Jul 07, 2021	HOLD	Hold +526.2% avg upside 1 analyst	$3.00 526.24% Upside	·
FR:VIRP Virbac SA	Jul 07, 2021	HOLD	Buy +6.0% avg upside 3 analysts	$270.00 20.19% Downside	·
GRFS Grifols SA	Jul 07, 2021	HOLD	Hold +245.9% avg upside 12 analysts	$27.66 279.95% Upside	-47.0%
LKFT Lakefront Biotherapeutics	Jul 07, 2021	HOLD	Buy +264.3% avg upside 24 analysts	$90.28 211.97% Upside	·
ARGX Argenx Se	Jul 07, 2021	HOLD	Strong Buy -16.2% avg upside 46 analysts	$251.41 72.10% Downside	+22.5%
FR:ABVX Abivax SA	Jul 07, 2021	BUY	Strong Buy -63.8% avg upside 3 analysts	$55.00 35.85% Downside	·
ES:ALM Almirall	Jul 07, 2021	BUY	Buy +18.6% avg upside 5 analysts	$15.40 37.65% Upside	·
GB:0R55 Bone Therapeutics	Jul 07, 2021	BUY	Strong Buy +259899.9% avg upside 1 analyst	$5.20 259899.95% Upside	·
FR:DBV DBV Technologies	Jul 07, 2021	HOLD	Sell +88.2% avg upside 3 analysts	$9.00 223.58% Upside	·
FR:ALCOX Nicox SA	Jul 07, 2021	BUY	Buy +1632.0% avg upside 5 analysts	$10.00 2552.50% Upside	·
FR:ALVIO Valerio Therapeutics	Jul 07, 2021	BUY	Buy +135.0% avg upside 3 analysts	$1.00 399.96% Upside	·
FR:IPN Ipsen	Jun 03, 2021	HOLD	Buy -24.1% avg upside 17 analysts	$79.00 49.79% Downside	·
DE:BAYN Bayer	Mar 03, 2021	BUY	Strong Buy +31.0% avg upside 28 analysts	$62.00 62.41% Upside	·
DE:93Z Marinomed Biotech AG	Nov 10, 2020	HOLD	Hold +1115.4% avg upside 1 analyst	$110.00 1115.40% Upside	·
VALN Valneva	Nov 10, 2020	BUY	Buy +107.1% avg upside 5 analysts	$6.86 28.12% Upside	-48.5%
BPTSY Biophytis	Nov 10, 2020	SELL	Sell +23.4% avg upside 2 analysts	$0.31 23.43% Upside	+96.9%
BAYRY Bayer	Oct 08, 2020	BUY	Buy +280.9% avg upside 9 analysts	$67.42 523.79% Upside	-8.5%
NVO Novo Nordisk	Nov 29, 2018	HOLD	Hold +153.0% avg upside 26 analysts	$290.00 532.15% Upside	+54.0%

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

David Evans — Frequently Asked Questions

How accurate are David Evans's stock ratings?

Based on the calls 13Foresight could measure, about 62% of David's ratings were profitable over a one-year hold, with an average return of +9.5% per rating, or +0.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is David ranked on 13Foresight?

David Evans is currently ranked #1012 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does David cover?

David most recently has ratings on GB:0QIU, CH:NOVN, DE:MRK, GB:AZN, GB:GSK, CH:ROP, GB:0NZT, FR:SAN, CH:ALC, FR:EAPI, GB:0G99, FR:TNG and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!